Role of mLST8 in mTORC2-dependent lung cancer that are refractory to targeted therapies
Congressional District Code:
Biomedical Laboratory R&D
April 2018 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
Project Summary/Abstract Lung cancer is the leading cause of cancer-related deaths in the US and disproportionally affects Veterans. Lung cancer subtypes that are currently refractory to targeted therapies include tumors carrying activated K-Ras or drug-resistant EGFR mutations, as well as tumors whose genetic alterations are “unknown”. Among the “unknown” category, Rictor (a unique component of mTORC2) amplification was recently identified as a driver genetic alteration in 11-13% of non-small c...